Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$614.29BAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sandeep Bakhshi
- Sector
- Financial Services
- Industry
- Banks - Regional
- Employees
- 124,324
- Beta
- 0.23
- Country
- IN
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.26
Financials
Revenue
$614.29B+278.5%Net Income
$154.40B+418.3%EBITDA
$213.74B-34.1%EPS (diluted)
$42.58-8.2%Shares Outstanding (diluted)
3.63B+7.5%Operating Expenses
$69.12BCash & Debt
$1.96TDividend per Share
$0.25Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $3.12T | $542.08B | $151.78 |
| 2025 | $2.95T | $510.29B | $144.82 |
| 2024 | $2.35T | $442.56B | $126.38 |
| 2023 | $1.85T | $340.37B | $97.72 |
| 2022 | $1.58T | $251.10B | $72.42 |
| 2021 | $1.61T | $183.84B | $54.52 |
| 2020 | $1.50T | $95.66B | $29.62 |
| 2019 | $1.31T | $42.54B | $12.62 |
| 2018 | $1.19T | $77.12B | $24.04 |
| 2017 | $1.13T | $101.88B | $31.84 |
| 2016 | $1.01T | $101.80B | $31.86 |
| 2015 | $902.13B | $122.47B | $38.50 |
| 2014 | $794.29B | $110.41B | $34.78 |
| 2013 | $741.70B | $96.04B | $30.30 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from IBN's reported EPS growth of 13.2% a year over 13 years.
- EPS in 5 years
- $282.13
- Implied price
- $4,514
- Return from $27.44
- 177.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2,244 — today's price is already 98.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| 3.2% | 138.8% | 146.3% | 153.0% | 159.0% | 164.5% |
| 8.2% | 150.4% | 158.2% | 165.2% | 171.5% | 177.3% |
| 13.2% | 162.0% | 170.2% | 177.5% | 184.1% | 190.1% |
| 18.2% | 173.5% | 182.1% | 189.7% | 196.6% | 203.0% |
| 23.2% | 185.1% | 194.0% | 202.0% | 209.2% | 215.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·3d ago·Neutral
IBN to Serve as Media Sponsor of The ThinkEquity Conference 2026 Corporate communications network to expand awareness of conference participants and presentations Corporate communications network to expand awareness of conference participants and presentations
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndicat…
View source ↗ - Newsglobenewswire.com·12d ago·Positive
IBN Announces Latest Episode of The MiningNewsWire Podcast featuring Dr. Bo Møller Stensgaard, President of Greenland Mines Ltd. AUSTIN, Texas, Sept. 24, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The MiningNewsWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication chann…
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc. AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd. AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. Disseminated on behalf of Onco-Innovations Ltd. , may include paid advertisements.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Galiano Tiramani, Co-CEO of BOXABL Inc. AUSTIN, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
View source ↗ - Newsglobenewswire.com·40d ago·Negative
IBN Initiates Coverage of Silynxcom Ltd. AUSTIN, Texas, Aug. 26, 2026 (GLOBE NEWSWIRE) -- via IBN – Silynxcom Ltd. (NYSE American: SYNX), a manufacturer and developer of ruggedized tactical communication headset devices, has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
IBN Initiates Coverage of AZIO AI Holdings, Inc. AUSTIN, Texas, Aug. 21, 2026 (GLOBE NEWSWIRE) -- via IBN – AZIO AI Holdings, Inc. (NASDAQ: AZIO), a technology infrastructure company focused on developing, owning, and operating artificial intelligence data centers, enterprise GPU compute infrastructure, digital power solutions, and high-performance computing, has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate co…
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
IBN Initiates Coverage of HWAL Inc. AUSTIN, Texas, Aug. 19, 2026 (GLOBE NEWSWIRE) -- via IBN – HWAL Inc. (OTC: HWAL), a diversified entertainment and intellectual property company, has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy.
View source ↗
Earnings
Sat, Oct 17(in 11 days)
Consensus estimate $0.40 per share
Typical surprise +7.5% (median, so one quarter with a near-zero estimate can't distort it)
- Sat, Jul 18$0.43 vs $0.40beat
- Sat, Apr 18$0.41 vs $0.39beat
- Sat, Jan 17$0.35 vs $0.38miss
- Sat, Oct 18$0.39 vs $0.37beat
- Sat, Jul 19$0.43 vs $0.40beat
- Sat, Apr 19$0.41 vs $0.37beat
Estimates and results for IBN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IBN officers and directors.
- Bought
- —
- Sold
- $3.0m
0 trades
4 trades
- Jha Rakeshsold
- Jha Rakeshsold
- Jha Rakeshsold
- Bakhshi Sandeepsold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (33d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 3, 2024 (13d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 3, 2024 (10d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Mar 17, 2023 (44d later)Sell$1,001 - $15,000
- Peter Meijerhouse · MI03 · disclosed Mar 16, 2021 (27d later)Sell$15,001 - $50,000
- Greg Gianfortehouse · MT00 · disclosed Aug 18, 2020 (14d later)Sell$15,001 - $50,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Feb 14, 2020 (32d later)Buy$15,001 - $50,000
- Greg Gianfortehouse · MT00 · disclosed Feb 5, 2020 (33d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.